DUBLIN, Aug. 1, 2019 /CNW/ -- Endo International plc
(NASDAQ: ENDP) announced today the appointment of Domenic Ciarico as Executive Vice President and
Chief Commercial Officer, Sterile and Generics, effective
immediately.
In this role, Mr. Ciarico will lead commercial strategy and
execution for Endo's Generics Pharmaceutical and Sterile Injectable
businesses which are marketed and sold under the Par Pharmaceutical
brand. He will report to Paul
Campanelli, President and Chief Executive Officer, and will
join the company's Executive Leadership Team. Most recently, Mr.
Ciarico served as Senior Vice President and General Manager of Par
Sterile Products where he was responsible for all aspects of the
U.S. sterile product business which delivered double-digit growth
under his leadership. Mr. Ciarico succeeds Tony Pera, President, Par Pharmaceutical, who
announced his retirement in April
2019.
"Domenic brings a deep knowledge of the healthcare industry, a
clear focus on customer needs, and a proven track record of
successful execution. Since joining Endo, he has successfully led
our Sterile Injectables segment and driven growth," said
Campanelli. "I am confident he will continue to build upon the
company's solid foundation in generics and strengthen our ability
to bring quality medicines to patients."
"I'm very excited to lead such a talented team as we continue to
be focused on building our portfolio and capabilities for the
future," said Ciarico. "We are proud to serve as a reliable,
quality supplier to our customers and look forward to building upon
these trusted relationships to best serve patients."
Prior to joining Endo, Mr. Ciarico spent 20 years with
AmerisourceBergen Corporation (ABC), a leading pharmaceutical
wholesaler and service provider. At ABC, Mr. Ciarico held several
roles of increasing responsibility, including Senior Vice President
of Health Systems, leading health systems sales and commercial
strategy. Prior to that, Mr. Ciarico was Group Vice
President, managing three of ABC's service businesses, including
American Health Packaging, Pharmacy Healthcare Solutions and
AmerisourceBergen Technology Group. Domenic holds a B.S. degree as
well as an M.B.A. from The Ohio State
University.
"I want to also acknowledge the dedication and accomplishments
of Tony Pera," added Campanelli.
"Tony has been a strategic member of my leadership team for the
past five years, substantially grew our Sterile Injectables
business and was critical to the repositioning of our Generic
Pharmaceutical business through prudent product selection during a
period of tremendous change and customer consolidation. On behalf
of myself and the board of directors, we would like to wish him all
the best in his retirement."
About Endo International plc
Endo International plc is a global specialty healthcare company
focused on improving patients' lives while creating shareholder
value. Endo develops, manufactures, markets, and distributes
quality branded pharmaceutical, generic and device products through
its operating companies. Endo has global headquarters in
Dublin, Ireland, and US
headquarters in Malvern, PA. Learn
more at www.endo.com.
Cautionary Note Regarding Forward-Looking Statements
Certain information in this press release contains certain
"forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995 and any applicable
Canadian securities legislation. Statements including words such as
"believes," "expects," "anticipates," "intends," "estimates,"
"plan," "will," "may," "look forward," "intend," "guidance,"
"future" or similar expressions are forward-looking statements.
Because these statements reflect our current views, expectations
and beliefs concerning future events, these forward-looking
statements involve risks and uncertainties. Investors should note
that many factors, as more fully described under the caption "Risk
Factors" in Endo's Form 10-K, Form 10-Q and Form 8-K filings with
the Securities and Exchange Commission and in
Canada on the System for
Electronic Data Analysis and Retrieval and as otherwise enumerated
herein or therein, could individually or in the aggregate affect
Endo's future financial results and could cause Endo's actual
results to differ materially from those expressed in the
forward-looking statements or from historical results. The
forward-looking statements in this press release are qualified by
these risk factors. Endo assumes no obligation to publicly update
any forward-looking statements, whether as a result of new
information, future developments or otherwise, except as may be
required under applicable securities laws.
View original
content:http://www.prnewswire.com/news-releases/endo-appoints-domenico-ciarico-as-executive-vice-president-and-chief-commercial-officer-sterile-and-generics-300894582.html
SOURCE Endo International plc